Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It reduces liquidity post data day ..
Dec 15th warrants have been extended to Feb and March ... ask Marzan he can confirm.
Stop profit order ...
probably got anther one 1.68-1.70
Pharma Competitor Landscape.
Every listed large pharma knows every single thing there is to know about not only their competitors but also their potential competitors as these same competitors and new tech developers of course become their acquisition targets.
The collective knowledge about our trial and its potential on just this anonymous message board is huge but its a piss in the ocean compared to what Large Pharma or even the likes of NVCR would know about DCVAX technology.
The recent breadcrumb trail of Poignant / NYSE up list , warrant extensions , end point changes & Flaskworks does not mean for one second that a deal is not ready to be inked.
The obvious buyer would be Merck and my god they`ve certainly got the war chest and cash flow to buy us in a heart beat but there are numerous other potential buyers...
Rest assured large pharma execs and their science Ph'ds of which they have hundreds will understand the potential of what we`ve got and pay a
lot for it.
I`m calling it $14bn so a nice even $10pps.
For me Id say that gets us all a handsome payoff for the pain of this tortuous journey and gets the vaccine to patients in the shortest possible time post top line.
Good call Soj , well done.
How can they have an offering when 100% they`ve got the data ..
Apparently when she grows up she wants to be an `influencer` ...
I watched the Olivia Voz video on NWBO technical analysis ... my god its pathetic ... don`t watch it .. don`t do it to yourself ...
I suspect the vast majority of her 19.5k followers might watch her vids for other reasons than her spewing ` the stock has got some upside but also some downside potential...` excrement ... jeeezus
The Street is the pits , its say Merck invested $125 Billion in 2018 .... total amateurs ...
they dont need build cash to buy they have $10bn in C&CE already
Example of NEGATIVE TLD PR :
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
OV101 program in Angelman syndrome to pause pending full analysis of NEPTUNE trial and discussions with FDA
Pivotal studies of OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome expected to begin in the First Half of 2021
NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced topline results from the Company’s Phase 3 NEPTUNE clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome.
NEPTUNE is a randomized, double-blind, placebo-controlled, Phase 3 study that enrolled and treated 97 patients diagnosed with Angelman syndrome, 4-12 years of age, and 7 patients diagnosed with Angelman syndrome ages 2-3 years for safety and pharmacokinetic evaluation only. The study was designed to assess the effects of treatment with OV101 (oral, once-daily dosing) versus placebo over 12 weeks. The sole primary endpoint was change in overall score on the Clinical Global Impression-Improvement-Angelman syndrome (CGI-I-AS) scale. Secondary endpoints included sleep, communication, motor function, socialization, daily living skills and behavior domains.
The primary endpoint of the NEPTUNE study was not achieved. Patients given OV101 showed a 0.7 point improvement in CGI-I-AS over baseline while placebo also showed a 0.8 point improvement in CGI-I-AS (p=NS). Secondary endpoints continue to be evaluated, although initial results show no difference between OV101 and placebo.
OV101 was well-tolerated, with no significant safety issues observed. Ovid plans to complete a full analysis of the results of the NEPTUNE study and discuss these results with the U.S. Food and Drug Administration (FDA) to determine next steps, if any, for the program. The Company will continue to offer study drug to patients enrolled in the open-label extension trial (ELARA) pending further analysis of the NEPTUNE study. The Company expects to report data from the ELARA study in the first quarter of 2021.
“We are deeply disappointed with the outcome of the NEPTUNE trial which did not achieve its primary endpoint,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. “Other than the ongoing ELARA study, we plan to pause our OV101 program in Angelman syndrome pending a full understanding of this outcome and discussions with regulators and investigators.”
Example of POSITIVE TLD PR , they all follow the same format , the headlines and a few supporting paragraphs, that`s it, no more no less .. is it really that friggin difficult...
Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
– 40 Percent of Patients Treated with Mitapivat Achieved a Sustained Hemoglobin Increase of ≥1.5 g/dL Compared to 0 Placebo Patients (p<0.0001) –
– Safety Profile Consistent with Previously Reported Data –
– Topline Data from the Mitapivat Phase 3 ACTIVATE-T Trial in Regularly Transfused PK Deficiency Expected in Q1 2021 –
CAMBRIDGE, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the global Phase 3 ACTIVATE trial of mitapivat in adults with pyruvate kinase (PK) deficiency who do not receive regular transfusions met its primary endpoint. Treatment with mitapivat demonstrated a statistically significant, sustained increase in hemoglobin compared to placebo. The safety profile observed in the study was generally consistent with previously published data. Mitapivat is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes.
“The robust, clinically meaningful efficacy and safety results from the ACTIVATE study underscore mitapivat’s potential to be the first disease-modifying therapy for people with pyruvate kinase deficiency, a chronic, lifelong hemolytic anemia that often leads to serious physical and quality of life complications. With only supportive therapy currently available, there is tremendous unmet need in this community, and we are proud to advance a promising therapeutic candidate for these patients,” said Chris Bowden, M.D., chief medical officer at Agios. “The results of this trial, which represent the first pivotal Phase 3 clinical data for mitapivat, support our hypothesis that mitapivat can improve the health, energy and longevity of red blood cells in patients with hemolytic anemias. We look forward to announcing ACTIVATET data in the first quarter of next year, and expect to file for regulatory approval in PK deficiency in both the U.S. and EU in 2021.”
Results from the ACTIVATE trial were as follows:
40 percent of patients randomized to mitapivat achieved a hemoglobin response, defined as a ≥1.5 g/dL increase in hemoglobin concentration from baseline that is sustained at two or more scheduled assessments at Weeks 16, 20 and 24 during the fixed-dose period, compared to 0 patients randomized to placebo (2-sided p<0.0001)
Treatment with mitapivat demonstrated statistically significant improvements over placebo across pre-specified key secondary endpoints, including average change from baseline in hemoglobin concentration at Weeks 16, 20, and 24 during the fixed-dose period; markers of hemolysis (indirect bilirubin, haptoglobin, serum lactate dehydrogenase [LDH] activity); and markers of hematopoietic activity (reticulocyte percentages).
The safety profile observed in the study was generally consistent with previously reported data.
There were no AEs leading to discontinuation in either the mitapivat or the placebo arm.
Agios is conducting a full analysis of the ACTIVATE data, including patient-reported outcomes (PRO) which are not yet available. The company expects to submit the complete results of the trial for presentation at the European Hematology Association (EHA) Virtual Congress, which is being held June 9-17, 2021.
Agios anticipates filing for U.S. and EU regulatory approval in adults with PK deficiency in 2021, with a potential 2022 commercial launch in both geographies.
Where on earth is the 10q ??
..and that means...
a) They have long since been unblinded
b) They have known whether they met end points weeks ago
c) No PR means end points were met
d) Extending warrants means end points were met
e) They can not raise cash before TLD being in receipt of material data
f) For once time decay is on our side
When someone wants to trade a stock , there’s only one way to do it and that’s via a regulated
institution , bank or broker . The trade will be fully electronic NO EXCEPTIONS .
If you want to buy well that’s easy all you need to do is give the order , price and size and as long as you’ve got the cash to cover the purchase it goes into the market and you await your fill or otherwise .
If you want to sell you have to already own the stock and it must be under custody/ safe keeping with the
house through who you wish to sell , however if you want to simply bet against the stock ie short it the broker will have to ‘ locate ‘ the amount of stock you wish to short electronically either in house or held at another broker shop .
When (IF) he finds said stock the cost of borrowing that stock to allow you to deliver it to whoever you were to sell to is charged as an interest rate .
The last rate NWBO traded at was 28%. which is an annual rate that the shorter would have had to pay to deliver the stock .
Last borrowed rate was 28% !
Thats when there was stock to borrow ...
..you cant see shares available just on BBG , you need a
`Markit` subscription on top of your BBg monthly sub.
`Markit`
Finally ZERO SHARES AVAILABLE TO BORROW ... Liquidity ZERO
last traded at 28%
It means that the liquidity on the offer side is restricted to just those shares that are held by the longs.
What it means is you cant borrow any shares in order to short.
Zero liquidity .
So any selling we see if from longs taken some risk off or some profit etc etc
Finally ZERO SHARES AVAILABLE TO BORROW ... Liquidity ZERO
last traded at 28%
Poignant is 100% on the NWBO books as a current consultant just in case there was any doubt about timing etc etc ..
So many clues that end points have been met...I believe the company have been unblinded for 6+ weeks.
We also know they are awaiting a major journal to give the green light on publishing the full and final data in conjunction with our TLD PR ... and of course Lancet publish every week so....
To me its ultra important because if they have asked for the extension we are 99% assured that we have met our main end points.
Marzan, on a previous post you said `we hear warrants pushed farther back` If that is the case and I am correct in my total belief that they are long since unblinded then that double reinforces, on top of the bad news rule, that everything must be positive because there`s no way they could ask share holders to extend warrants if there was ANY bad news ...
Thanks Danish Dude, whoever you are ! .. :)
Twitterers
Someone please get a post on Twitter showing we have Poignant NYSE Listing specialist as a Consultant
`Mr Bigger` is a shark that would have your eyes our of your head and come back for the sockets ..
He`d short NWBO as quickly as he bought and in any case how much did he actually buy on the open market .. and you know what I`d bet a great deal he was the scumbag that sold 40m in a day exactly a month ago.
OK Sukus lets leave it there ... you and I are in different worlds.
Sukus , well yes I`ve been in the business a long time albeit not quite 60 years although it sometimes feels like it... but I assure you Sukus
`shaking the tree` is self soothing codswallop, you`d do well to not buy into it... metaphorically of course..
ha thats right .. I think...
if we knew it would be worth x 3 next week it would already be there ...
no no no no .... thats like saying isnt the traffic good today ...
its wrong
Dont bother - 1 trillion % he doesnt